{
  "id": 12835297,
  "title": "Goldman Sachs initiates Vylor stock with buy rating on tech shift",
  "url": "https://urgent.news/2026/10/08/goldman-sachs-initiates-vylor-stock-with-buy-rating-on-tech-shift",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-08T09:32:55.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/goldman-sachs-initiates-vylor-stock-with-buy-rating-on-tech-shift-93CH-4938271"
  },
  "original_language": "en",
  "account": "Goldman Sachs recently began covering Vylor Inc (NYSE: VYLR) with an \"initiate\" rating, projecting a buy rating and a price target of $87.00 per share. This target suggests a 19% increase from Vylor's current stock price of $72.99 and surpasses the analyst consensus high target of $85. The firm attributes the rating to the company's shift towards a high-growth, asset-light technology platform. Vylor presents a competitive advantage with Bayer and benefits from a five-to-seven-year seed replacement cycle, contributing to an approximate 4% annual revenue growth and 8% EBITDA growth. In the previous year, Vylor generated $17.81 billion in revenue, maintaining a strong gross profit margin of 49.5%, although analysts predict a slight revenue decline in the current year. Despite this, the stock appears overvalued according to InvestingPro's Fair Value analysis, with a high P/E ratio of 41.8. Goldman Sachs anticipates growth acceleration through the commercialization of their proprietary non-GMO hybrid wheat using Xpedite technology, which aims to eliminate historical cost barriers and position wheat as the third major crop alongside corn and soy. By leveraging its scale and gene-editing expertise, Vylor is transitioning toward a high-margin out-licensing model, expanding its total addressable market while decreasing capital intensity. The $87 price target is based on an 85% fundamental and 15% M&A valuation, equating to an 17.5x FY28E EV/EBITDA multiple. Vylor's post-spin valuation premium allows for strategic M&A acquisitions to integrate advanced traits into acquired germplasm. Vylor has recently gained attention from multiple financial analysts following its separation from Corteva, solidifying its status as an independent seed and genetics company.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Goldman Sachs sees China petrochemical oil demand decline reversing",
        "url": "https://urgent.news/2026/10/08/goldman-sachs-sees-china-petrochemical-oil-demand-decline-reversing",
        "published": "2026-10-08T08:35:29.000Z"
      },
      {
        "outlet": "Seeking Alpha News",
        "title": "Palantir in focus as Goldman Sachs upgrades on recent underperformance",
        "url": "https://urgent.news/2026/10/08/palantir-in-focus-as-goldman-sachs-upgrades-on-recent-underperformance",
        "published": "2026-10-08T12:05:45.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}